Second quarter financial results is a catalyst that should continue to affirm CV Sciences long-term prospects amidst the patent concerns raised by Citron Research. The stellar financial results also underscore the fact that the company has been successful in executing its strategy of aggressive and consistent sales growth.
CV Sciences has also done an excellent job in expanding its distribution channels, a move that has allowed it to strengthen its market share within the CBD natural products market. PlusCBD product line continues to affirm the company’s operating performance which is the number one product in the hemp CBD product category.
CV Science share price has dipped significantly in response to the claims about a key patent. Amidst the concerns, the company’s fundamentals remain intact, if the recent quarterly financial results are anything to go by.
Speculation about the company’s patent should subside going forward, given that the company has shown it has what it takes to be a force to reckon with in the industry. The fact that the company turned in a profit for the first time in the second quarter, also underlines what is at stake as it continues to execute on its business strategy.
News 
Market Data 
Discover 
AI
